ESR1 and breast carcinoma: This study reported that the level of expression of IP-10 was higher in breast cancer tumors of the basal subtype as compared to ER+ tumors and that IP-10/CXCR3 axis could serve as a potential target in BRCA1 and basal breast cancers that involve increased lymphocytic infiltration and a poor prognosis [45].